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Abstract: Chronic viral disease constitutes a major global health problem, with several hundred
million people affected and an associated elevated number of deaths. An increasing number of
disorders caused by human flaviviruses are related to their capacity to establish a persistent infection.
Here we show that Usutu virus (USUV), an emerging zoonotic flavivirus linked to sporadic neurologic
disease in humans, can establish a persistent infection in cell culture. Two independent lineages of
Vero cells surviving USUV lytic infection were cultured over 82 days (41 cell transfers) without any
apparent cytopathology crisis associated. We found elevated titers in the supernatant of these cells,
with modest fluctuations during passages but no overall tendency towards increased or decreased
infectivity. In addition to full-length genomes, viral RNA isolated from these cells at passage
40 revealed the presence of defective genomes, containing different deletions at the 5’ end. These
truncated transcripts were all predicted to encode shorter polyprotein products lacking membrane
and envelope structural proteins, and most of non-structural protein 1. Treatment with different
broad-range antiviral nucleosides revealed that USUV is sensitive to these compounds in the context of
a persistent infection, in agreement with previous observations during lytic infections. The exposure
of infected cells to prolonged treatment (10 days) with favipiravir and/or ribavirin resulted in the
complete clearance of infectivity in the cellular supernatants (decrease of ~5 log10 in virus titers and
RNA levels), although modest changes in intracellular viral RNA levels were recorded (<2 log10
decrease). Drug withdrawal after treatment day 10 resulted in a relapse in virus titers. These results
encourage the use of persistently-infected cultures as a surrogate system in the identification of
improved antivirals against flaviviral chronic disease.
Keywords: chronic viral infection; emerging arboviruses; defective viral genomes; antiviral therapies;
lethal mutagenesis
1. Introduction
Chronic viral infections constitute a major challenge to global public health, with several hundred
million people affected and significant associated fatalities [1–6]. Viral persistence in the host generally
leads to different pathogenic outcomes including the exacerbation of medical conditions [7]. Apart from
their direct relationship with disease, viral persistence in animal reservoirs has also been linked to the
re-emergence of pathogenic viruses [7]. In addition to major viral agents causing chronic infections, such
as hepatitis C virus (HCV) and human immunodeficiency virus [3,8], there is an increasing incidence
of chronic disease caused by arboviruses [6,9–11]. In the flaviviruses, the ability to persist seems to be
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limited to neurotropic strains. However, in addition to neurological infection, it has been documented that
flavivirus persistence also occur in different cells and tissues outside the nervous system [6]. In particular,
West Nile virus (WNV) has been isolated from the urine of patients with a history of infection and
suffering from chronic renal disorders [12,13]. Further evidence supporting an association between
chronic disease and persistent kidney infection has been obtained with animal models for WNV and other
flaviviruses [12,14–17]. Besides severe neurological disorders linked to acute infection (e.g., Guillain–Barré
in adults and congenital brain defects in neonates), Zika virus (ZIKV) establishes persistence in different
cells and tissues, leading to an array of other medical conditions [9,18,19]. Persistent ZIKV in both
male and female reproductive tracts is connected to sexual transmission of infection [18,20], and also to
mother-to-fetus transmission from vaginal infected tissue [18,21]. Tick-borne encephalitis virus (TBEV)
and Japanese encephalitis virus (JEV) also cause chronic disease associated with persistence. Progressive
chronic TBEV was documented in a patient who died ten years after infection [22], while JEV was
detected in the cerebrospinal fluid of infected patients for several weeks to >100 days after the onset of
symptoms [23]. The ability of flaviviruses to persist is not limited to their vertebrate hosts as they can
also infect their vectors for long periods. WNV can be detected in different mosquito tissues for at least
4 weeks after infection [24,25] while TBEV replicates in ticks for periods exceeding 100 days [26]. The life
of ticks can be several years which could potentially help to propagate persistent flaviviruses in their
vertebrate hosts multiple times during a lifetime.
While most flaviviruses generally trigger apoptotic cell death in vitro, many of them can establish
a persistent infection in different cultured cells. Specifically, TBEV can persist in the human embryonic
kidney (HEK) 293T cell line for at least 35 weeks without any cytopathic effect crisis observed [27,28].
Viral RNA levels remained constant during the whole period although virus titers decayed after four
weeks. This drop in infectivity was linked to the emergence of defective interfering (DI) particles,
although the establishment of persistence could not be directly related to them. TBEV defective
genomes presented a deletion partially affecting envelope (Env) and non-structural protein 1 (NS1)
genes [27]. Transcriptome analysis of these persistently-infected cells revealed increased expression
of survival genes and downregulation of apoptosis-associated factors [28]. Cell models of flaviviral
persistence have also been established in insect cells [29,30]. TBEV persistence in different tick cell
lines led to similar evolutionary trends as those observed in HEK cells, with virus titers detected
for >100 days, a tendency to lower plaque sizes, and different adaptive mutations in the Env gene,
although no DI particles were found [26].
Cell culture lineages persistently infected with viruses represent tantalizing models in the study
of chronic infection in vitro and the characterization of antiviral drugs [31,32]. Most culture models for
flaviviruses typically involve a lytic infection, leading to the death of the cell monolayer. However,
these systems may be less adequate for examining the efficacy of inhibitors that need to be administered
during a prolonged period. For HCV, a virus genetically related to arthropod-transmitted flaviviruses
(both belong to the Flaviviridae family), there have been developed cell culture systems of persistent
infection which bear some degree of resemblance to chronic infection in patients [32–34]. Tissue culture
models for persistent HCV have replicated the efficacy of multidrug therapies currently used in the
clinical treatment of infection, including sofosbuvir [32]. These precedents encourage the establishment
of cell culture methods for different viruses, such as the flaviviruses, as possible surrogate models to
examine persistence and to identify drugs with improved efficacy.
In this study, we have investigated the capacity of Usutu virus (USUV) to establish persistence in
African green monkey kidney epithelial cells (Vero cells). These cells are permissive to most human
flaviviruses, and are generally employed in their propagation and biological characterization. USUV is
an emerging threat, rapidly spreading in different wild and captive birds in Europe, and causing large
mortality in some species, e.g. blackbirds [35,36]. Although USUV infection in humans is typically
asymptomatic, there has been reported an increasing number of neurological cases resembling WNV
infection. The incidence of USUV infection in humans seems to be on the rise, with a record number of
infected people in Austria during 2018 [37,38]. There is evidence suggesting that increased incidence
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of disease in humans is geographically connected to outbreaks in birds [39–43]. Besides, human cases
of USUV disease might have been historically misdiagnosed as WNV, underlining the relevance of this
pathogen as an emerging threat to global health, and the need for new tools for its study [39,40,44].
Owing to its close relationship to WNV, which is known to cause chronic infection in humans, it is
conceivable that USUV can also establish persistence in its hosts.
Here, we have isolated two independent lines of Vero cells that became persistently infected after
surviving an apparently lytic infection with USUV. The advantage of including two cellular lineages
is that those biological features reproduced in both lines may be more relevant to understanding
viral persistence. We showed that persistently-infected cells were successfully maintained for 82 days
(41 passages), with viral infectivity positively detected in all the cellular supernatants. The genetic
analysis of viral RNA extracted from the cells after 40 passages revealed the presence of both full-length
and defective viral genomes in each cell line. Different in-frame deletions (>2 Kb) were identified, all of
them located at the 5’ end of the viral RNA. These truncated genomes are predicted to encode shorter
viral polyproteins lacking partially or entirely several structural proteins (membrane (M), its precursor
(PrM), and envelope (Env) proteins) and non-structural protein 1 (NS1).
To calibrate the efficacy of this cell culture model in the study of antiviral compounds, we have
used three broad-range nucleoside analogues that we previously examined during a lytic infection [45].
In our earlier work, we demonstrated that ribavirin (RBV), favipiravir (FAV), and 5-fluorouracil (FU)
elicit a strong antiviral activity associated with viral mutagenesis [45]. Under certain experimental
conditions, we observed complete virus extinction after five consecutive lytic passages in the presence
of these drugs [45]. Additional in vivo evidence of the antiviral efficacy of FAV against USUV has been
obtained by Segura Guerrero and colleagues using a mouse model of lethal infection [46]. In this study,
we found that these compounds also exhibit antiviral activity against persistent USUV. Prolonged
exposure to RBV, FAV, or a combination of both drugs (F + R) can lead to the complete extinction of
infectivity and viral RNA in the cellular supernatants. However, significant amounts of intracellular
viral RNA were yet detected in these cells, suggesting that USUV escapes extinction by mutagenesis in
a persistently-infected cell context. We discuss the possible value of persistently-infected cell models
for the identification of new antiviral compounds against the flaviviruses. We posit that these methods
may permit the characterization of antiviral activity during extended treatment periods, and thus be
instrumental to the identification of improved drugs against chronic infection.
2. Materials and Methods
2.1. Cells, Virus, and Establishment of Persistently Infected Cultures
To this study we used an USUV strain isolated from infected birds in Austria (2001) and provided
by Giovanni Savini from Istituto G. Caporale, Italy [45,47]. The viral stock used for this study was
obtained after seven USUV passages in cell culture. For propagation and titration of viral samples we
employed Vero cells as previously described [45]. Cells were grown in media containing 5% (v/v) fetal
bovine serum (FBS, Sigma, St. Louis, MO, USA), 100 units/mL penicillin–streptomycin (ThermoFisher,
Waltham, MA, USA) and 1 mM Hepes in high glucose DMEM (ThermoFisher), and maintained at
37 ◦C with 5% CO2.
For the establishment of persistently-infected cultures we seeded 1 × 106 Vero cells in 35 mm
culture dishes, and incubated them overnight at 37 ◦C in the presence of 5% CO2. We then removed
the cellular supernatant and inoculated USUV at a multiplicity of infection (MOI) of 0.01. Extensive
cytopathic effect was observed at 48 h post-infection although we found that ~20% of the cells remained
attached to the plate even at later post-infection times (Figure 1). At 48 (line V) or 96 h post-inoculation
(line S), unattached dead cells were removed by washing the plate three times (using fresh media or
PBS). Those cells surviving the infection were supplemented with fresh media and, after reaching
confluence, trypsinized and seeded in a new flask. The established cell lines were then passaged every
48 h by transferring 3–4 × 106 cells to a new 75 cm2 flask in each passage.
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2.2. Virus Titration
To analyze virus titers, cellular supernatants were collected from persistently-infected cells (at
48 h post-seeding) before each cell passage. The presence of infectious virus in these supernatants was
determined by 50% tissue culture infectious dose (TCID50) assays as previously described [45]. Briefly,
to each well of a 96-well plate 1 × 104 Vero cells in 60 µL of media containing 5% FBS was added.
On the following day, 100 µL of 10-fold serial dilutions of each viral sample, in media containing 1%
FBS, was applied to each well, reaching a final volume of 160 µL. The virus titers were determined by
scoring the number of infected wells showing apparent cytopathic effect at day 5 post-infection, and
using the Reed and Muench method [48,49].
2.3. Treatment with Antiviral Compounds
To determine the 50% inhibitory concentration (IC50) for each drug treatment, we seeded
2 × 104 cells per well in a 96-well plate. On the following day, cell supernatants were removed
and 100 µL of 1% FBS complete media containing 5-fluorouracil (2,4-dihydroxy-5-fluoropyrimidine,
Sigma-Aldrich), ribavirin (1-(β-d-Ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide, Sigma-Aldrich),
favipiravir (6-fluoro-3-hydroxy-2-pyrazinecarboxamide, Atomax) or a combination of ribavirin and
favipiravir at concentrations ranging from 25 to 2000 µM was added. Cells were incubated at 37 ◦C
and in the presence of 5% CO2, and supernatants containing virus were collected at different time
points for subsequent analyses.
Cell toxicity assays were performed on 96-well plates using the same drugs and concentrations
abovementioned for IC50 assays. Toxicity was recorded using the CellTiter–Blue Cell viability assay
(Promega, Madison, WI, USA), which accounts for living active cells, following the indications provided
by the manufacturer.
To examine the effect of antiviral nucleosides upon persistent USUV during prolonged treatment,
we seeded 1 × 105 cells per well in a 24-well plate. On the following day, cell culture supernatants were
removed and 1 ml of 1% FBS complete media containing 2000 µM ribavirin, favipiravir, or a combination
of ribavirin and favipiravir were added. Cells were incubated at 37 ◦C and in the presence of 5% CO2.
2.4. Viral RNA Extraction, RT-PCR Amplification, and Sequence Analysis
Viral RNA was extracted from either 100 µL of cell supernatants or directly from whole cell
monolayers grown in 24-well plates, using GeneJET RNA Purification Kit (ThermoFisher). To amplify
the USUV viral RNA molecules, we followed a two-step RT-PCR amplification procedure. Briefly, 4 µL
of purified RNA extracted from whole cell monolayers were reverse-transcribed in a final volume
of 20 µL using SuperScriptIII (Roche, Basel, Switzerland), as indicated by the manufacturer. Three
microliters of cDNA were then PCR amplified using AccuPrime Taq DNA Polymerase High Fidelity
as indicated by the provider (Thermofisher). To generate overlapping amplicons covering the entire
USUV genome, we used primers spanning genomic positions: 1 to 55 (sense) and 7950 to 7929; 4218 to
4189; 3359 to 3335 or 2673 to 2653 (antisense); 818 to 842 (sense) and 3359 to 3335 (antisense); 2976 to
3009 (sense) and 7950 to 7929 (antisense); and 6841 to 6864 (sense) and 11066 to 11016 (antisense). PCR
products were directly extracted with a QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) or
individual PCR bands on an agarose gel were purified using the PureLink Quick Gel Extraction Kit
(Invitrogen, Carlsbad, CA, USA). The resulting PCR products were Sanger sequenced (LGC Genomics,
Berlin, Germany). Full genome sequences of our stock virus (passage 0) or USUV adapted to persistence
(S and V cells at passage 40) were compared to the reference strain (Genbank ID: AY453411) using the
CLC Main Workbench program [47].
2.5. Quantitative PCR Analysis of Virus Populations
To detect total viral RNA in the sample (including both standard and defective genomes), we used
a protocol previously described [45,50]. Briefly, in this assay we used sense and antisense primers,
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and a FAM–TAMRA probe targeting the NS5 gene (position 9297 to 9318). For the amplification
of the RNA sample we used TaqMan Fast Virus 1-Step Master Mix (ThermoFisher) and one-step
RT-PCR amplification conditions, with a reverse-transcription step (30 min at 48 ◦C) followed by
1 min incubation at 95 ◦C and 40 amplification cycles of 15 s at 95 ◦C and 1 min at 60 ◦C. For the
specific quantification of full-length genomes (excluding defective genomes lacking Env) we used
primers targeting the Env protein-coding gene spanning residues 1462 to 1486 (sense) and 1559 to 1540
(antisense). For this method we used One-Step TB Green PrimeScript RT-PCR Kit II (Takara, Tokyo,
Japan) and one-step RT-PCR amplification conditions, with a reverse-transcription step (5 min at 42 ◦C)
followed by 2 min incubation at 95 ◦C and 40 amplification cycles of 15 s at 95 ◦C and 30 s at 60 ◦C.
To obtain a standard curve of known amounts of viral genomes, samples were prepared with USUV
RNA extracted from lytically-infected cells. To quantify the number of viral RNA molecules present in
the extract we used known amounts of USUV cDNA (plasmid containing USUV genomic positions
8965 to 10,398) and the FAM–TAMRA method abovementioned. Once viral genome concentration was
determined, the reference USUV RNA used to prepare the standard curve was distributed in aliquots
of 5–10 µL in low-biding tubes and stored at −80 ◦C. For each qPCR experiment we used fresh aliquots
(only frozen–thawed once) and discarded them after the experiment. The standard curve samples
were prepared on the same day as the qPCR assay by diluting our reference USUV RNA to a final
concentration of 109 viral RNA molecules/µL in 100 ng/µL yeast RNA. This sample was serially diluted
1:10 in yeast RNA to generate aliquots containing 108–100 molecules/µL. Two independent sets of
standards were prepared for each qPCR plate.
2.6. Statistical Analysis
Statistical significance was determined using GraphPad Prism 8 (LaJolla, CA, USA) as specified in
each corresponding figure legend.
3. Results
3.1. Establishment of Cell Lines Persistently Infected with USUV
To establish persistently-infected cultures we inoculated USUV onto two monolayers of Vero
cells that are subsequently referred as V and S lines (Figure 1). At 48 h post-infection extensive
cytopathic effect was observed, with an estimated ~80% of cells detaching from the plate (Figure 1B).
To remove detached dead cells, we extensively washed the plates with fresh media at 48 h (lineage V)
or 96 h (lineage S). Cell monolayers surviving the infection were cultured normally and, after reaching
confluence, the monolayer was trypsinized and transferred to a new flask using standard procedures
for the passage of non-infected cells. V and S cells exhibited normal growth, modestly slower than Vero,
leading to confluent monolayers of similar appearance (Figure S1). V and S cell lines were maintained
for 82 days (41 transfers) by serially passaging them every second day (Figure 1). No apparent lytic
crises were observed during the passages.
To investigate whether the surviving cells had become infected, we analyzed the presence of
infectious virus (TCID50 assay) and viral RNA (qPCR) in the cellular supernatants. Both cell lines
showed elevated titers along the whole passage history, suggesting that infectious USUV is continuously
shed by these cells to the extracellular environments. Notably, cellular supernatants collected from
persistently-infected cells (which showed no cytopathology) caused normal cytopathic effects during
infection on regular Vero cell cultures, permitting virus titration as normal. This observation may be
indicative of V and S cells becoming resistant to lytic infection. Viral titers fluctuated between 105 and
108 TCID50/mL although no overall tendency to higher or lower virus yields were observed during
the passages (m is 0.01 and 0.00 for cell lines V and S, respectively). USUV specific infectivity, which
measures the ratio between infectious virus particles and viral genomes, was decreasing along passages
(Figure 1E,F), with larger viral RNA levels detected in the supernatant of later samples (Figure 1D).
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This might be indicative of USUV infectivity losses associated with long-term persistence in cell culture,
in agreement with previous observations for other flaviviruses [27].Viruses 2019, 11, x FOR PEER REVIEW 6 of 21 
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PCR amplicons covering the USUV 5’-end genome revealed the presence of large deletions in both V 
and S cells (Figure 2). In V cells, we identified three bands of different sizes in amplifications of the 
5’ end region, one corresponding to the expected length and two other bands of lower molecular 
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square) at an MOI of 0.01. At 48 (V cells) or 96 h (S cells), unattached dead cells re removed and
the surviving cells cultured in fresh media. Cells are passaged every 48 h using standard procedures.
(B) Percentage of cells that remain attached to a 16- m dish at 48 or 120 h after USUV (grey) or mock
infection (black). These values are relative of mock-infected cells at 48 h post-infection. (C) USUV titers
in persistently-infected cells along passages. Viral titers in S cells supernatants are represented as black
circles, V cells as white squares. (D) Viral RNA in cell supernatants of V (white squares) and S cells
(black circles) along passages. The number of molecules in each passage was determined by qPCR
using primers targeting the Env-coding region. (E) and (F), USUV specific infectivity in the supernatant
of V (E) and S cells (F). Specific infectivity is determined as the ratio between infectious units (TCID50)
and the number of viral genome equivalents detected in the samples. Statistically significant differences
are represented by asterisks (*** p < 0.001). Two-way ANOVA test.
To characterize the genetic alterations associated with long-term persistence, we sequenced the
entire USUV genome isolated from persistently-infected cells after 80 days (passage 40). Different PCR
amplicons covering the USUV 5’-end genome revealed the presence of large deletions in both V and S
cells (Figure 2). In V cells, we identified three bands of different sizes in amplifications of the 5’ end
region, one corresponding to the expected length and two other bands of lower molecular weight.
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Further sequence analysis confirmed the presence of two in-frame deletions in these amplicons of 2.5
and 2.1 Kb (∆585–3053, ∆872–2971). In S cells, we detected a single dominant band ~2.5 Kb shorter
than the expected size in each of several PCR amplifications of 5’ USUV RNA (Figure 2B, see amplicons
I, III, and IV). Sequence analysis of these samples revealed the presence of two major in-frame deletions
of similar size, spanning residues 584 to 3184 (2.6 Kb) and 680 to 3121 (2.4 Kb), which may account for
this apparent single band. Standard genomes were detected in S cells only when primers annealing
to the deleted region were used (Figure 2B, PCR amplicons V and VI), suggesting that the absence
of full-length genome products in PCRs I, III, and IV may be due to a preferential amplification of
truncated variants. All these deletions were predicted to render in-frame truncations of the polyprotein
lacking the Env protein and most of NS1 (Figure 2). In three of these four truncated genomes the
complete loss of structural M protein was also predicted.
Viruses 2019, 11, x FOR PEER REVIEW 7 of 21 
 
weight. Further sequence analysis confirmed the presence of two in-frame deletions in these 
amplicons of 2.5 and 2.1 Kb (Δ585–3053, Δ872–2971). In S cells, we detected a single dominant band 
~2.5 Kb shorter than the expected size in each of several PCR amplifications of 5’ USUV RNA (Figure 
2B, see amplicons I, III, an  IV). Sequence analysis of these samples revealed the presence f two 
m jor in-frame d letions of similar size, spanning residues 584 to 3184 (2.6 Kb) and 680 to 3121 (2.4 
Kb), which may account for this apparent single band. Standard genomes w re detected in S c lls 
on y when primers annealing to the deleted region were used (Figure 2B, PCR amplicons V and VI), 
sugg sting that the abs nce of full-length genom  products in PCRs I, III, and IV may be due t  a 
preferential am lificatio  of truncated variants. All these deletions were predicted to render in-frame 
truncations of the polyprotein lacking the Env protein and most of NS1 (Figure 2). In three of these 
four truncated genomes the complete loss of structural M protein was also predicted. 
 
Figure 2. USUV genomes containing large deletions in the 5’ end are detected in persistently-infected 
cells. (A) Schematic representation of USUV genome, PCR amplification strategy, and deletions 
identified. Top panel, illustration of USUV genome. Each box represents a different viral protein-
coding region. White boxes represent genomic sequences encoding structural proteins (C, capsid; M, 
membrane protein; PrM, M precursor; Env, envelope) and grey boxes depict non-structural proteins 
(NS1 to NS5). Different deletions are indicated by a thick dark grey line below the corresponding 
truncated sequence. Bottom panel, PCR amplification strategy (only shown those corresponding to 
PCR gel analyses below). Each predicted amplicon is represented as a thick light grey line (I to VI). B 
and C, amplification products of viral RNA extracted from persistently-infected cells at passage 40 
(p40) or cells infected with wild type USUV (p1). Amplification of viral RNA from S (B) and V cells 
(C) and compared to USUV wild type. The amplification products were run on a 1.5% agarose gel in 
the presence of 0.5× TBE for 35 min. PCR bands in persistently-infected cells (p40) of lower molecular 
Figure 2. USUV genomes containing large deletio s i r etected in persistently-infected
cells. (A) Schematic representatio of lification strategy, and deletions
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Each predicted amplicon is represented as a thick light grey line (I to VI). B and C, amplification
products of viral RNA extracted from persistently-infected cells at passage 40 (p40) or cells infected
with wild type USUV (p1). Amplification of viral RNA from S (B) and V cells (C) and compared to
USUV wild type. The amplification products were run on a 1.5% agarose gel in the presence of 0.5×
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TBE for 35 min. PCR bands in persistently-infected cells (p40) of lower molecular mass than those
found in the standard genome (p1) are indicated with an arrow. Viral RNA from S p40 (B) amplified
with primers spanning residues 818 to 3359 (amplicon V) revealed the presence of a new deletion
product (~1.5-Kb shorter than in wild type virus). This new truncation was not apparent in larger
amplification products (amplicons I, III, and IV). (D) Detail on USUV genomic sequences surrounding
the deletion sites. The deleted sequences are represented between brackets. Nucleotide positions
immediately upstream and downstream of the deleted sequence are numbered according to reference
USUV sequence AY453411. There is no apparent homology in the genomic regions surrounding the
nucleotides at the joining site, except for the first sequence provided, with putative identities underlined.
3.2. Quantification of Truncated and Standard Viral Genomes in Persistently-Infected Cells
To quantify the relative amount of full-length genomic RNA to total viral RNA (including both
standard and defective genomes) we used two different qPCR quantification methods specifically
targeting two genomic regions: Env and NS5 (Figure 3). The qPCR approach for the detection of the
Env gene (absent in defective viral RNA molecules) is predicted to identify standard genomes only.
As anticipated, we found lower amounts of viral RNA in V and S cells when using qPCR methods
for Env than for NS5. No significant differences were obtained for viral RNA extracted from cells
infected with wild type USUV (Figure 3B,C), in agreement with the absence of defective genomes in
this sample (Figure 2B,C, sample p1). From this analysis we estimate that 71% of viral genomes in S
p40 cells are truncated (29% of standard genomes) while in V p40 cells 46% of genomes are defective
(54% of standard genomes). This is in agreement with better PCR detection of full-length genomes in
samples isolated from V cells than in S cells (Figure 2B,C, amplicons I, III, IV).
The quantitative analysis of viral RNA in cellular supernatants also suggests the release of particles
containing truncated genomes to the extracellular environment, as lower proportions of standard USUV
genomes are detected in S and V cells than in Vero cells infected with wild type USUV (Figure 3D,E,
Figure S2). The analysis of extracellular samples from different passages also supports the presence of
defective genomes starting from an early passage in both V and S lines (Figure 3F, Figure S2).
3.3. Non-Synonymous Mutations are Accumulated in USUV Proteins NS4A and NS4B
Full-length genome sequencing of viral RNA isolated at passage 40 revealed the presence of
four repeated nucleotide substitutions in both V and S cell lineages. These changes included two
silent mutations in the Env and M coding regions, and two non-synonymous mutations in NS4A and
NS4B-coding regions, leading to amino acid replacements E45N and T92M, respectively (Table 1).
Another amino acid replacement in NS4A (F24L) was also found in both lines, although it was the
result of different nucleotide changes (Table 1). In addition to these three amino acid replacements
repeatedly found in both viruses, other changes were identified in these two proteins (E22D in NS4A;
L89R, Y127H and M172R in NS4B), supporting an adaptive role to persistence in cell culture.
Table 1. Genomic differences between parental stock (wild type) and persistent USUV (isolated from V
p40 and S p40), and compared to the USUV reference strain (GenBank ID: AY453411).
Nucleotide
Position
USUV
Parental Stock S p40 V p40 Viral Gene
Amino Acid
Replacement
G775 * A A A M E9K
C891 1 U U M −
C1815 1 U U Env −
C3661 U NS2A −
A3867 G NS2A −
C4958 U NS3 T118M
C5432 * U U U NS3 A276V
G6528 U NS4A E22D
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Table 1. Cont.
Nucleotide
Position
USUV
Parental Stock S p40 V p40 Viral Gene
Amino Acid
Replacement
A6532 2 C NS4A F24L
U6534 2 A NS4A F24L
G6595 1 C C NS4A E45N
U7175 G NS4B L89R
C7184 1 U U NS4B T92M
U7197 * G G G NS4B F96L
U7288 C NS4B Y127H
U7424 G NS4B M172R
A10311 * G G G NS5 −
* An asterisk denotes sequence differences between our USUV stock and the reference strain from which it derives
(Genbank ID AY453411). 1 Those nucleotide substitutions were found in both V and S persistently-infected cells. 2
Two different nucleotide substitutions in V and S cells are leading to the same amino acid replacement.
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standard and defective genomes) we used two different qPCR quantification methods specifically 
targeting two genomic regions: Env and NS5 (Figure 3). The qPCR approach for the detection of the 
Figure 3. etection of defective viral geno es in ersistently-infected cells. (A) Illustration of S V
geno e and target sequence sites for iff r t str te ies. Different deletions found in and S
defecti s are shown as thick dark grey lines, and a square indicates the common delete region
in these different sequences. The procedures for each qPCR detection meth d are described in Materials
and Methods. Methods for the detection of non-structural protein 5 (NS5)-coding regio are used for
the quantification of total viral RNA molecules (including both standard and truncated viral genomes).
Methods for the detection of the Env-coding region are used for the specific detection of standard
genomes (excluding defective genomes). (B,C) Intracellular detection of viral RNA. B, quantification of
intracellular viral RNA in lytically- and persistently-infected cells using qPCR detection methods for
Env (black bars) or NS5 (grey bars) coding regions. Each bar represents the average of values obtained
from independent cell monolayers (n > 5). (C) Estimated ratio of standard length genomes in the
sample (viral RNA molecules detected with Env relative to NS5, based on results shown in (B). (D,E)
Same as in B and C but in samples extracted from cellular supernatants (n > 3). (D) Quantification of
extracellular viral RNA using qPCR detection methods for Env (black bars) or NS5 (grey bars) coding
regions. Each bar represents the average of values obtained from independent cell monolayers (n > 5).
(E) Estimated proportion of full-length genomes in the supernatant of V and S cells at p40, and Vero
cells infected with wild type USUV. (F) Proportion of full-length genomes in the supernatants of S
and V cells along passages. Statistically significant differences are represented by asterisks (* p < 0.05,
** p < 0.01, *** p < 0.001). B and D, one-way ANOVA test. C and E, two-way ANOVA test.
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3.4. Broad-Range Nucleoside Drugs Strongly Inhibit Persistent USUV
To characterize this cell culture system of infection as a tool in antiviral research, we examined the
efficacy of three broad-spectrum antivirals (i.e., FU, FAV, and RBV) against persistent USUV. We have
recently demonstrated that USUV is sensitive to all these drugs during a lytic infection [45]. In our
previous study, we found reduced USUV titers (and complete viral extinction under certain regimes)
in experiments involving five consecutive lytic passages in Vero cells treated with 800 µM FAV, RBV,
or FU. These antiviral activities were linked to increased mutagenesis in the populations rescued from
treated cells. Here, we have observed that continuous treatment of persistently-infected V and S cells
with FU, RBV, or FAV also results in decreased virus titers in the cellular supernatants (Figure 4), with
FU and RBV being more effective against USUV than FAV (Table 2). The IC50 values obtained for each
drug were similar in different cellular contexts but slightly lower for persistently-infected cultures. The
selectivity indexes for these compounds were relatively high for all these drugs, except for Vero cells
treated with FU which showed elevated toxicity. We decided to investigate if a combination of FAV and
RBV (F + R) could lead to improved antiviral activities (Figure 4D,H). We observed generally lower
IC50 values for an F + R cocktail than for each drug alone suggesting that it could lead to improved
efficacies in the treatment of USUV infection (Table 2).
Table 2. Antiviral activity of nucleoside analogues against USUV in lytically and persistently-infected
cells.
Cell Line Compound IC50 (µM) CC50 (µM) Selectivity Index
Vero cells 5-Fluorouracil 71 66 1.1
Favipiravir 315 >2000 >6.3
Ribavirin 163 >2000 >12.3
Favipiravir + Ribavirin 60 * >2000 * >33.3
V p39 5-Fluorouracil 42 467 11.1
Favipiravir 197 >2000 >10.2
Ribavirin 71 >2000 >28.2
Favipiravir + Ribavirin 36 * >2000 * >55.6
S p39 5-Fluorouracil 56 472 8.4
Favipiravir 241 >2000 >8.3
Ribavirin 80 >2000 >25.0
Favipiravir + Ribavirin 78 * >2000 * >25.6
The 50% cytotoxic concentration (CC50) and the 50% inhibitory concentration (IC50) were extrapolated from nonlinear
regression curves obtained from experiments represented in Figure 4 (n = 3). * An asterisk indicates that this value
is for each independent drug. Thus the IC50 in these samples for both drugs taken into consideration together are
120, 72, and 156 µM, respectively. The CC50 values would be all >4000 µM.
3.5. Prolonged Treatment with Nucleoside Drugs Abolishes Infectivity in Persistently-Infected
Cell Supernatants
To investigate whether prolonged exposure to a cocktail of F + R could be effective in curing
persistently-infected cells, we treated V and S cells for 6 consecutive days in the presence of a
concentration of 2000 µM for each drug. We initially tested the antiviral activity of an F + R combination
for 6 days on both V and S cells (Figure S3). By day 5 we found undetectable levels of infectious virus
in S and V cell supernatants. However, a relapse in viral infectivity was observed when treatment
was discontinued (days 7 to 10), suggesting the presence of infectious virus intracellularly and/or at
undetectable levels in the supernatant (Figure S3B). We also observed a lytic crisis in both cell lines
associated with this viral relapse. Lytic crises were never observed in V and S cells during standard
passages (Figure S1).
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Figure 4. Antiviral nucleosides inhibit USUV persistent infection in Vero cells. A-D, Cellular toxicity
displayed by different nucleoside drugs was test d upo V p39 (grey triangl s), S p39 (grey ci cles), and
uninfect Vero c lls (black squares), u ing th CellTiter–Blue Cell viability a say (Prom ga), which
accounts for living cells. Cellu r viability was measured in cells treated with increasing concentrations
of 5-fluorouracil (FU) (A), favipiravir (FAV) (B), ribavirin (RBV) (C), or FAV + RBV (D) at 48 h and
represented as a relative value to untreated cells (n = 3). (E,F) Viral titers recovered in V p39 (grey
triangles), S p39 (grey ci cl s), and lytically-infected Vero cells (black squares), after 48h in th presence
of nucleoside drug analogues. Valu s observed in cells treated with increasing concentrations o FU
(E), FAV (F), RBV (G), or FAV + RBV (H). To this as ay, naïve uninfected Vero cells (black squares) were
in culated with wild type USUV at an MOI f 0.01, and after adsorption the cells were treated with
drugs for 48 h. Persistently-infected V p39 and S p39 were directly treated with drugs for 48 h. Every
time point is the av rage of three (n =3) biological replicas (±SEM). In FAV + RBV graphs (D,H) the
ordinate values represent the concentration for e ch drug individually (e.g. 400 µM refers to a cocktail
of 400 µM FAV and 400 µM RBV, or 800 µM nucleosides).
To further investigate the dynamics of virus extinction by antiviral nucleosides in persistently-
infected ells, and whether longer expo ure t these drug could lead to completely curing infection,
we s t up a larger xperiment to analyze irus titers and RNA levels at different time points (Figure 5).
Owing to the fact that both cell lines show similar susceptibilities to antivir l nucleosides (Table 2,
Figure S3) we decided to perform this experiment with S cells only. We lso anticipated that since S
cells release lower virus titers tha V cells at passage 39 (Figure 1C, Figure 4E–H), it might be easier to
achieve the complete curing of infectivity. For this assay, we treated S p39 cells for 10 days with FAV,
RBV, or F + R at a concentration of 2000 µM for each drug. Low toxicity profiles and precedent studies
in vitro and in vivo support the use of such an elevated drug concentration for this assay [51–53].
We observed that all three different treatments elicited similar efficacy against USUV, leading to the
complete extinction of infectious virus in the cellular supernatant of persistently-infected cells by day 6
(Figure 5B). To certify viral extinction, these supernatants were serially passaged in naïve Vero cells
and in the absence of drugs (Figure 5C). This process was repeated three times, using a new monolayer
of cells in each passage. With the exception of RBV-treated cells at day 6, no infectivity was recovered
in samples collected at days 6−10 for any of these treatment regimes (Figure 5C). This observation
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supports that prolonged treatments of S p39 with RBV and/or FAV can eliminate persistent USUV in
infected cells.
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Figure 5. Treatment with FAV, RBV, or a combination of both can cause complete loss of infectivity in
cell supernatants. (A) Schematic representation of the experimental procedure. For each treatment,
six independent monolayers of S p39 cells were seeded (n = 6). Whole monolayers (RNA extraction)
and supernatants (RNA and virus titers) of untreated or treated cells were collected at days 2, 4, 6, 8,
and 10 (n = 1). (B) Virus infectivity in S p39 cells treated with FAV, RBV, or a cocktail of both drugs
(F + R) at 2000 µM each drug. A dotted line represents the limit of detection. (C) Virus titers recovered
after a blind infection in naïve Vero cells using 100 µL of S p39 cell supernatants obtained in B after
treatment. Those samples containing undetectable virus levels (dashed line) remained negative when
two additional blind passages in Vero cells were performed (not shown). (D,E) Viral RNA levels in the
supernatants of treated cells, using qPCR methods based on the detection of NS5- (D) and Env-coding
regions (E). (F,G) Specific infectivity (SI) of USUV genomes detected in the cellular supernatants of
treated cells. SI is calculated as the ratio of infectious units (B) to viral RNA molecules (D and E). SI
based on qPCR methods for the detection of NS5 (F) or Env (G) genes.
This loss in infectivity was also accompanied by dramatic decreases in the viral RNA levels.
By day 10, viral RNA was barely detectable in FAV or RBV-treated cells, and it was completely absent in
F + R series, suggesting the complete extinction of USUV in the cellular supernatant (Figur 5C,D). The
specific infectivity of USUV was significantly lower in supernatants collected from treated cells than in
untreat d cells (Figure 5E,F). Decreases in specific infectivity are a typical feature of virus populations
approachi g extinction as a consequence of lethal mutagenesis. This would be in agreement with
our previous observations where we documented a antiviral activity li ked to increase USUV
mutagenesis during a lytic infection [45].
3.6. Interruption of Drug Treatment Results in the Recovery of Viral Infectivity
To examine whether S p39 cells treated for 10 days had been completely cured of the infection, we
cultured these monolayers for three additional days in the absence of drugs (Figure 6). We found that,
after drug removal, USUV infectivity re-emerged in the supernatant of cells previously treated with
RBV or FAV only (Figure 6B). Those cells that had been treated with an F + R cocktail did not show any
recovery of infectivity by day 3, even when the supernatant collected was passaged in consecutive
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blind infections (Figure 6C). However, further culturing of F + R cells in the absence of drugs led to
the recovery of infectivity by day 5 (Figure 6D), and complete cytopathology of the monolayer was
observed at day 7, as previously observed in experiments described above (Figure S3).Viruses 2019, 11, x FOR PEER REVIEW 13 of 21 
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Figure 6. USUV infectivity re-emerges in the supernatant of persistently-infected cells after drug
withdrawal. (A) Experimental procedure. Cells were treated for 10 days in the presence of FAV, RBV,
or a combination of both (F + R) at a concentration of 2000 µM for each drug (n = 1). After 10 days, drugs
were removed and cells cultured for 3 (FAV and RBV) or 7 additional days (F + R). (B) Viral infectivity
(TCID50/mL) detected in the supernatant of cells after 10-day drug treatment followed by 3 days in the
absence of drugs. (C) Viral infectivity recovered after three serial passages of cellular supernatants
collected in B. In each blind infection, 100 µL of supernatant from the previous passage was used to
infect a new monolayer of Vero cells. After adsorption for 1 hour, fresh media was added and cells
were incubated for 24 additional hours at 37 ◦C. (D) Viral infectivity (±SEM) in the supernatant of S
cells treated with F + R for 10 days followed by absence of treatment for 3, 5, and 7 days. (B–D) A
dashed line represents the limit of detection.
3.7. Loss of Extracellular Infectivity is not Accompanied by Intracellular Extinction of USUV
All this evidence suggested that, despite the complete extinction of infectivity in the supernatants
of treated cells (days 6–10), infectious viral genomes may be replicating intracellularly and escaping
treatment. To investigate this possibility we analyzed the presence of viral RNA in whole cell RNA
extracts isolated at different time points (Figure 5A). We confirmed that, despite the rapid extinction of
infectious particles and viral RNA in the extracellular environment (Figure 5B–D), there were relatively
large intracellular levels of viral RNA detected (Figure 7). By treatment day 10, the amount of viral RNA
in cells was only 1.5-log10 lower than in mock-treated cells, in striking contrast with the large decreases
in virus titers and RNA levels observed in the supernatant of the same cells (~5-log10 decrease). To rule
out that this disparity may be due to a distinct sensitivity to drugs in standard and defective genomes,
we used both qPCR techniques abovementioned to detect either Env- or NS5-coding regions. We
confirmed that the intracellular decrease of standard full-length viral genomes was similar to that
observed for total viral RNA, which is indicative of a similar susceptibility to drugs in both truncated
and standard genomes (compare Figure 7A,B). Thus, our data suggests that the recovery of infectivity
after drug withdrawal is due to the replication of competent intracellular viral genomes that have
escaped the antiviral treatment.
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Figure 7. Intracellular viral RNA detected in S p39 persistently-infected cells treated with antiviral
drugs. These RNA extracts were obtained from the experiment represented in Figure 5A. Viral RNA
levels detected in whole cell monolayer extracts after treatment with FAV, RBV, or a combination of both
drugs (F + R) at a concentration of 2000 µM for each drug. For each treatment regime, 6 independent
wells were seeded (n = 6) and samples were collected at different time points (n = 1). Quantitative PCR
(qPCR) methods, based on the detection of NS5- (A) and Env-coding regions (B) are used. A dashed
line represents the limit of detection.
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have been documented [11,44,54,55]. Thus, the devel pment of novel cell cultur models can be
in trumental to further characterize flaviviral infection and to identify more effe tive antiviral th rapies.
In this study we have demonstrated that USUV, n emergi g zoon t c threat to humans, can establish
a pers stent infection in V ro cells where it replicates robustly for at least 80 days (Figure 1). V and S
ells exhibited no mal growth, modestly slower t an Ve o, eading to confluent monolayers of similar
appearances (Figure S1). However, V and S cultures showed larger contact inhibition, lower te dency
to gr w in multiple yers, and contained larger numbers of round cells detached from the monolayers
(Figure S1). None heless, no lytic crises were report d during the whole passage history and extended
culture times (e.g., 120 h) did not lead to any increase in the number of detach d cells (Figure S1).
The use of cell culture syst ms has been proposed as a conceivabl surrogate approach to
characterize the d terminants that regulate a persistent infection in the host. In particular, cell culture
systems of infection have been developed for HCV, a pathogen genetically related to flaviviruses
transmitted by vectors [31,32]. HCV is a major global cause f viral c ronic disease with estimates
uggesting that 70 million p ople ar currently infected [56]. Although these cel culture systems are
not aimed at replicating the complex networks implicated in the establishment of chronic infection
in vivo, they can assist in identifying the c llular genes that are distinctly r gulated during persistenc ,
and developing more effective therap utics required during prolonged treatments [28,32]. While
there is yet no evidence of USUV establishing persistence in vivo, the fact hat subclinical infections
occur in birds and humans underpins this possibility [35,37,38]. For closely related WNV, a p hogen
causing significant numbers of cases of hr nic diseas in humans, it has been found that most natural
infections in its mammalian hosts (humans, hor es) are subclinical [57]. To the present date, th re
are limited studies in vivo with USUV which hind the possible development of ani al model
of persistence [46,58,59]. USUV causes an asy ptomatic infection i wild type mice or chickens
which encourages using th se animal models to develop systems of study persistence in vivo [58,59].
Alt rnatively, in so e bird species USUV develops an asymptomatic or mild infection which could
therefor be exploited as plausible animal models of persistence.
The use of cell culture ines can help identify thos host genes that are distinctly expressed
during persistence relative to the acut phase of vir l infection. This information can b relevant
to unraveling the networks activated or inhibited in cells surviving infection. The identification
Viruses 2019, 11, 560 15 of 21
of these host factors can be exploited in the design of antiviral therapies based on drugs targeting
them. Evidence supporting the use of in vitro models in the characterization of the cellular and viral
determinants modulating persistence has been obtained for TBEV [28]. These precedents stimulate
prospective studies to identify the determinants modulating USUV persistence in S and V cells. To this
aim, we could make use of different approaches such as comparative transcriptomics or whole cell
proteomics of persistently- and lytically-infected cells. For TBEV, a comparative transcriptomics profile
revealed that prosurvival oncogenes, such as AKT2 and ERBB2, were overexpressed in persistently
infected cells while proapoptotic genes, such as Bad and beta interferon-1, were downregulated [28].
Despite the lack of knowledge regarding the mechanism by which USUV establishes persistence,
we anticipate that defective viral genomes (DVGs), containing truncations of variable length at the
5’ end, may be playing a major role in this process, in agreement with several lines of evidence [6,7].
All the truncated genomes described here are predicted to encode a polyprotein lacking Env, most of
NS1, and partially PrM/M (Figure 2). This is suggestive of these structural genes, and possibly NS1,
playing a major role in triggering cell death. A connection between the cytopathic effect observed in
flavivirus-infected cells and the expression of Env has been established [6]. The emergence of DVGs
lacking or containing truncated versions of Env and NS1 during persistence has been described for
other flaviviruses [6,27]. In particular, in TBEV-persistently infected cells, genomes have been identified
that lack almost the entire Env-coding region and the N-terminal domain of NS1 [27]. There have
also been found deletions in Env and NS5 proteins of dengue virus-2 persistently infecting mosquito
cells [60]. In Vero cells persistently infected with Murray Valley encephalitis virus the presence of
genomes encoding a truncated NS1 have been documented [61]. In a recent study, WNV genomes
isolated from infected birds revealed the presence of truncated genomes containing large deletions,
leading to the complete loss of Env and portions of NS1 and PrM/M, similar to what we have observed
in USUV [62].
Indirect evidence from nucleoside drug experiments described above underpins the idea of DVGs
having a protective role for the host cell. We found that antiviral treatment followed by drug removal
generally led to increased cell death associated with the relapse in infectivity (Figure S3B and Figure 6D).
We posit that decreased intracellular viral RNA levels (Figure 7), which include DVGs, leave the cells
‘unprotected’ against re-infection by fully infectious virus. Further investigations are needed to clarify
whether DVGs actually interfere with full-length USUV genome replication, and contribute to cell
survival and persistence. There are at least three hypotheses to explain the contribution of defective
genomes to persistence. A first model to explain the role of DVGs during persistence sustains that DI
particles emerge during standard virus replication and, when they become dominant in the infected cell,
they interfere with standard viral genome replication, further decreasing its presence in the cells [6,7].
A second hypothesis based on recent data for Sendai virus posits that DVGs stimulate pathways of
cell survival while cells containing elevated amounts of standard genomes follow apoptotic routes [7].
A third model supports that DVGs protect cells from death by a mechanism known as superinfection
exclusion, consisting of the ability of an established virus infection to prevent subsequent infections in
the same cell. Superinfection exclusion has been described in BHK-21 cells harboring a subgenomic
WNV replicon (synthetically produced) which exhibited lower susceptibility to virus infection than
naïve cells [63]. WNV superinfection exclusion could be reversed by treating the replicon-bearing cells
with a virus inhibitor [63], which is in agreement with increased cytopathology observed in USUV
persistently-infected cells after treatment with antiviral drugs.
We hypothesize that this cell culture system for persistent USUV can be instrumental in the
identification of effective therapeutics in the control of infection. In recent years, USUV has caused a
modest but growing number of cases of human disease, mainly affecting European countries [38,43,44,64].
Several lines of evidence are also hinting at a possible underestimation of the incidence of human
disease, with several cases of USUV misdiagnosed as WNV [37,39]. Here, we observe the complete
elimination of infectious virus in the extracellular environment of cultures treated with broad-range
antiviral nucleosides FAV and RBV at a concentration of 2000 µM. However, relatively large viral RNA
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levels remained detected intracellularly. While drug concentrations used in our cell culture system
are elevated, several lines of evidence suggest that for FAV these levels can be reached in vivo [53,65].
In a non-human primate model of Ebola/Marburg virus infection, treatment with 150 mg/Kg/day FAV
led to plasma concentrations of ~1500–2000 µM one hour after dosing [53]. Our results suggest that
intracellular viral genomes (both truncated and standard) resist the antiviral activity elicited by these
nucleosides and, when drug treatment terminates, they replicate normally and rescue infectivity. We
envisage future experiments to further investigate the disparity observed between the intracellular and
extracellular environments. In particular, we deem of utmost interest identification of the virus life
cycle steps inhibited by these nucleosides (e.g., protein translation, encapsidation, viral egress) which
could be accountable for the absence of infectious particles outside the cell. A tentative explanation
is that a vast majority of USUV intracellular genomes are replicative-defective RNA molecules as a
consequence of an excessive accumulation of mutations in the presence of FAV and/or RBV. Supporting
this hypothesis, we have observed significant decreases in the specific infectivity of viral genomes in the
cellular supernatants of cells treated for 2 to 4 days (Figure 5F,G).
We have previously examined the efficacy of these drugs against USUV during lytic infections,
and established an association between the antiviral activities observed and increased virus mutation
frequencies [45]. The use of nucleoside drugs eliciting increased virus mutation rates is currently being
investigated as an alternative antiviral strategy known as lethal mutagenesis [52,66,67]. An advantage
of therapies based on mutagenic nucleosides, such as those used in this study, is that the antiviral
effect associated with mutagenesis (i.e., detrimental mutations) is accumulated during viral RNA
synthesis, and thus can be propagated to offspring genomes. In theory, mutagenic drugs should be
more effective against persistent infections since longer periods of infection entail higher number
of replication cycles, and hence larger number of mutations accumulated. Several lines of evidence
from clinical and in vivo studies endorse this hypothesis. We have previously demonstrated that FAV
is effective in curing persistent murine norovirus infection in mice, and recent data further support
FAV efficacy against chronic norovirus in humans [68,69]. The therapeutic potential of FAV has been
recently demonstrated in a mouse model of lethal USUV infection which encourages additional studies
to confirm whether this activity is linked to mutagenesis in vivo [46]. Likewise, RBV has been broadly
used in the clinical treatment of patients chronically infected with HCV [70]. Notably, in cell culture
systems of HCV persistent infection (Huh-7.5 cells) an autophagic response is observed which results
in lysosomal degradation of a nucleoside transporter (equilibrative nucleoside transporter 1) utilized
by RBV to enter the cell. Persistently infected-cells showed reduced intake of RBV, and hence lower
sensitivity to treatment [31]. Additional data confirmed that sensitivity to RBV was regained in
HCV-infected cells treated with autophagy inhibitors which restored nucleoside transporter levels in
the cellular membrane [31]. It remains to be demonstrated, however, whether flavivirus persistent
infection leads to alterations in the levels of nucleoside transporters that could be affecting cellular
sensitivity to antiviral drugs. Although our virus titer inhibition data may be suggesting the opposite
(USUV is more susceptible to drugs during persistence), these compounds exhibit lower toxicity in
persistently-infected cells than in Vero cells, in agreement with this possibility (Figure 4, Table 2).
Full genome sequence analysis of USUV has identified the presence of several non-synonymous
mutations, most of them accumulated in the NS4A and NS4B coding regions. Both NS4A and NS4B
proteins interact with each other in the infected cell, and the determinants of this interaction have been
characterized for dengue virus [71]. The residues in NS4A that participate in direct contact with NS4B
include positions 19 to 22 in α-helix 1 (18 to 21 in USUV), and residues A40, A44, and L48 in α-helix
2 (A39, A43, and L47in USUV) [71]. Several amino acid changes identified in our study are in close
proximity to residues involved in the interaction with NS4B (Table 1). In particular, mutations E22D
and F24L are close to residues 18–21 in helix α1 aforementioned, and E45N is located within residues
A39, A43, and L47 in α-helix 2. The mutation T92M in NS4B, which is repeatedly found in both V and
S cell lineages, is also located in the NS4B domain predicted to interact with NS4A (Table 1) [71]. The
accumulation of these non-synonymous mutations suggests that a strong selective pressure operates on
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these proteins during USUV persistence. A tantalizing possibility is that these amino acid changes are
leading to protein–protein binding alterations which could be favoring persistence in the infected cells.
Flavivirus NS4A and NS4B proteins are essential to the viral life cycle. Both viral products are
directly implicated in membrane rearrangements of the endoplasmic reticulum (ER) needed for the
formation of the replication complex, and the induction of autophagic pathways that prevent death of
the infected cell [72–75]. Although some studies suggested that flavivirus NS4A alone is sufficient to
induce prosurvival PI3K-dependent autophagy, recent findings with ZIKV have revealed that both
NS4A and NS4B can cooperatively suppress the Akt-mTOR pathway and trigger autophagy [73,76,77].
For several flaviviruses including USUV, it has been demonstrated that autophagy inhibitors elicit
an antiviral activity [75,78]. These findings together with the observations above on the impact of
autophagy on cell antiviral sensitivity encourage future investigations on the therapeutic value of drug
cocktails including nucleoside analogues and autophagy inhibitors.
We posit that some of those genetic alterations identified in persistent USUV are provoking its
attenuation in Vero cells, thus facilitating cell survival to infection. We now aim to investigate whether
these changes are leading to USUV infectivity losses not only in mammalian but also in other avian
and insect cell lines. These prospective studies can help reveal the viral determinants that modulate
virulence in vertebrate and invertebrate hosts.
5. Conclusions
The development of cell culture systems based in persistent flavivirus infection can be instrumental
to better understanding the intracellular rearrangements implicated in chronic viral disease. Cellular
models of persistent infection can also provide better surrogates for in vitro systems to examine
the efficacy of antiviral compounds in the treatment of chronic infection. We have validated our
model using old-known antivirals which exhibited sustained activity and suppressed detectable viral
infectivity in the cellular supernatants during prolonged periods, although virus relapse occurred when
drugs were removed. These results encourage the use of this model of infection for the identification
of improved therapeutic drugs against the flaviviruses.
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